Michael Palfreyman

Michael Palfreyman is a highly experienced professional in drug discovery and development, holding multiple senior roles including Senior R&D Advisor and Chief Research and Development Officer at Cybin Inc since December 2020, and Scientific Advisor for the Stanford Research Institute's Biosciences Division since March 2018. Michael also serves as President of Palfreyman BioPharm Advisors, Inc., and maintains a position as Senior R&D Diligence and Scientific Advisor at Torrey Pines Investment, Inc. Additionally, Michael has held leadership positions in various biotech firms, such as Chief Operating Officer at Adelia Therapeutics, Inc., Chairman of the Scientific Advisory Board at Aminex Therapeutics, Inc., and Chief Scientific Officer at Amorsa Therapeutics, Inc. Michael's educational background includes a Doctor of Science in Rational Drug Design and multiple PhDs in Neurobiology and Pharmacology from the University of Nottingham.